1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  

This page is powered by Blogger. Isn't yours?

Friday, September 16, 2016

 

Protein Linked to Alzheimer’s Shows Potential to Improve Memory
























Researchers at the Salk Institute, in California, have shown, in a mouse study, that increasing the levels of a specific protein in the brain leads to improvement of memory deficits associated with Alzheimer’s disease.

The new study, titled “Neuregulin 1 Improves Cognitive Deficits And Neuropathology In An Alzheimer’s Disease Model,” was published in the journal Scientific Reports.

The protein, neuregulin-1, has several forms and functions in the brain, most of which are known to play an important role in many disorders, such as Parkinson’s disease, autism, amyotrophic lateral sclerosis and schizophrenia. Other studies have suggested that neuregulin-1 may exert a protective effect by inducing a decrease in the levels of amyloid precursor protein, a molecule that generates amyloid beta, which is the primary component of the plaques that accumulate in the brain of Alzheimer’s patients, or by protecting neurons against the damage caused by blockage of blood flow.

“Neuregulin-1 has broad therapeutic potential, but mechanistically, we are still learning about how it works,” Kuo-Fen Lee, the lead author of the study, said in a news release. “We’ve shown that it promotes metabolism of the brain plaques that are characteristic of Alzheimer’s disease.”

In this study, the team tested, in mice, the effect of increased levels of two forms of neuregulin-1, one at a time in the hippocampus, the brain region responsible for memory and learning. Researchers observed that both forms of neuregulin-1 were able to improve animal performance on a test of spatial memory, and that markers of Alzheimer’s, such as amyloid beta and plaques, had lower levels compared to the control animals.

The team believes that neuregulin-1 induced the expression of another protein, neprisylin, which is able to degrade amyloid beta and thus prevent the formation of plaques. However, the protein also may have other roles that contribute to its beneficial effect, such as improving signaling between neurons, which is altered in Alzheimer’s disease.

A neuregulin-1 treatment is currently undergoing trials as a possible therapy for Parkinson’s disease and chronic heart failure. Since this is a protein that can enter the blood brain barrier (a barrier that selects what enters the brain and what does not), a potential treatment with neuregulin-1 would not require an invasive procedure.

Researchers are currently trying to reproduce their results in other models while studying other relevant aspects that may support a possible treatment with neuregulin-1 for Alzheimer’s disease. For instance, as other studies suggested that too much neuregulin-1 can have an undesired effect on the brain, the team is testing a small molecule that can increase the levels of existing neuregulin-1, instead of administering more protein. They also are investigating the possible link between schizophrenia and psychosis in late-onset Alzheimer’s, as neuregulin-1 has been associated with both disorders.

Story Source: The above story is based on materials provided by ALZHEIMERSNEWSTODAY
Note: Materials may be edited for content and length
Click here to read more